BPR-6023021

· Chengdu Syncor Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BPR-6023021, covering 2025-11-25 to 2025-11-25. Get the full timeline:

Most recent: Clinical Trial Update: A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases [Phase 1, Phase 2]